drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T-cell)
drug_description
Autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting guanylyl cyclase C (GCC). Patient T cells are engineered to express a GCC-specific CAR and, after intravenous infusion, recognize GCC-positive tumor cells and mediate cytotoxic killing and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a guanylyl cyclase C (GCC)-specific chimeric antigen receptor. After intravenous infusion, the CAR T cells recognize GCC on tumor cells, become activated, and induce tumor cell lysis through perforin/granzyme-mediated cytotoxicity and cytokine release.
drug_name
XKDCT080
nct_id_drug_ref
NCT05875402